Cargando…

Corrigendum: Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection

Detalles Bibliográficos
Autores principales:	Jhang, Jia-Fong, Jiang, Yuan-Hong, Hsu, Yung-Hsiang, Ho, Han-Chen, Birder, Lori A, Lin, Teng-Yi, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Continence Society 2022
Materias:	Corrigendum: Correction of the IRB number
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260320/ https://www.ncbi.nlm.nih.gov/pubmed/35793995 http://dx.doi.org/10.5213/inj.2221050.corrigendum

Ejemplares similares

Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma
por: Lee, Yu-Khun, et al.
Publicado: (2022)

Corrigendum: Vojta Approach Affects Neck Stability and Static Balance in Sitting Position of Children With Hypotonia
por: Ha, Sun-Young, et al.
Publicado: (2022)

Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2020)

Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome—A Comparative Study of Different Injection Number, Additives and Concentrations
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2019)

Pathophysiology, clinical presentation, and management of ketamine-induced cystitis
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Sensory Receptor, Inflammatory, and Apoptotic Protein Expression in the Bladder Urothelium of Patients with Different Subtypes of Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Abnormal Sensory Protein Expression and Urothelial Dysfunction in Ketamine-Related Cystitis in Humans
por: Tsai, Yao Chou, et al.
Publicado: (2016)

Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease
por: Jhang, Jia-Fong, et al.
Publicado: (2016)

Interstitial Cystitis Can Be Improved With Intravesical Instillation of Platelet-Rich Plasma
por: Hardy, Timothy J
Publicado: (2022)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Bladder Ultrastructure and Urinary Cytokine Abnormality in Patients with Recurrent Urinary Tract Infection and the Changes after Intravesical Platelet-Rich Plasma Injections
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2016)

Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency
por: Ke, Qian-Sheng, et al.
Publicado: (2019)

Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics
por: Lee, Yu Khun, et al.
Publicado: (2021)

Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition
por: Jhang, Jia-Fong, et al.
Publicado: (2018)

Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment
por: Yu, Wan-Ru, et al.
Publicado: (2021)

Interstitial cystitis intravesical therapy
por: Ha, Tanya, et al.
Publicado: (2017)

Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm
por: Jiang, Yuan-Hong, et al.
Publicado: (2021)

Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions
por: Yu, Wan-Ru, et al.
Publicado: (2023)

Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Risk Assessment of Medical Study Procedures in the Documents Submitted to a Research Ethics Committee
por: Happo, Saara, et al.
Publicado: (2020)

Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome
por: Birder, Lori, et al.
Publicado: (2018)

Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Wang, Hsiu-Jen, et al.
Publicado: (2019)

The Early Histological Effects of Intravesical Instillation of Platelet-Rich Plasma in Cystitis Models
por: Dönmez, M. İrfan, et al.
Publicado: (2016)

Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4
por: Yang, Hsueh-Hui, et al.
Publicado: (2021)

Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis
por: Chiu, Bin, et al.
Publicado: (2016)

Review of intravesical therapies for bladder pain syndrome/interstitial cystitis
por: Cvach, Kristina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_elqfm0hko2f4qb3calg88l1gen